Medical Device News Magazine

Bill Hoffman Joins Magenta Medical’s Board of Directors

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

William (Bill) Hoffman has joined Magenta Medical’s Board of Directors as an independent industry expert. Magenta Medical is developing the Elevate™ System, the smallest heart pump in the world.

Mr. Hoffman currently serves as a member of the board of directors of Inari Medical, where he was CEO from 2015 until 2022. In May 2020, he led the company to a successful IPO. Prior to Inari Medical, Mr. Hoffman served as CEO of Visualase, Inc., and VP of Sales at FoxHollow Technologies, acquired by Medtronic and ev3, respectively.

Magenta is developing a next-generation temporary mechanical circulatory support system that addresses the important shortcomings of current systems around insertion size and flow. The team is mission-driven, and I love their commitment to treat underserved populations, improve patient outcomes, and save lives,” said Mr. Hoffman.

Bill Hoffman is a widely respected and accomplished leader in the MedTech industry. The company is certain to benefit from his experience and insights as it looks to achieve its upcoming clinical milestones and future commercial goals,” said Dr. David Israeli, CEO of Magenta Medical.

About Elevate™

The Elevate™ percutaneous Left Ventricular Assist Device (pLVAD) is a miniaturized heart pump that fits a 9 Fr delivery system, providing the smallest crimping profile in the industry. The ElevateTM Pump can be inserted over a guidewire, using a 10 Fr commercially available femoral introducer sheath. The flow of the pump is adjusted based on the clinical circumstances of the patient and can exceed 5 L/min of mean flow. This makes it the most powerful device of its kind.

Elevate™ is an investigational device, limited by federal law to investigational use only. The technology was awarded Breakthrough Device Designation from the US Food and Drug Administration (FDA) for two indications: high-risk percutaneous coronary intervention (HR-PCI) and cardiogenic shock.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”